文献速递胸部肿瘤放疗

局限期小细胞肺癌患者接受同步加速超分割放疗与化疗后放射性肺炎的发生率及治疗结局

Incidence and Treatment Outcome of Radiation Pneumonitis in Patients With Limited-stage Small Cell Lung Cancer Treated With Concurrent Accelerated Hyperfractionated Radiation Therapy and Chemotherapy.
PubMed 文献 · Adv Radiat Oncol · 2022-11-23

本研究纳入2002年9月至2018年2月间125例接受早期同步加速超分割放疗(45 Gy/30次,每日两次)联合依托泊苷铂类化疗的局限期小细胞肺癌患者,中位随访73.1个月。≥2级放射性肺炎与肺V30≥20%强相关,且为独立危险因素;放射性肺炎中位发生时间为放疗开始后147天,经糖皮质激素治疗后可控制。

要点

  • ≥2级放射性肺炎与肺V30≥20%强相关,多因素分析显示V30≥20%为独立危险因素。
  • 放射性肺炎中位发生时间为放疗开始后147天,发生时间可能较晚。
  • ≥2级放射性肺炎经糖皮质激素治疗后可控制,未出现复发。

核心结论

  • ≥2级放射性肺炎的发生率与V30≥20%强相关,且V30≥20%为独立危险因素。
  • 同步加速超分割放疗联合化疗所致放射性肺炎的发生时间可能较晚。
  • 局限期小细胞肺癌患者的放射性肺炎可控制。

研究设计与样本

  • 回顾性分析2002年9月至2018年2月间125例接受早期同步加速超分割放疗联合化疗的局限期小细胞肺癌患者。
  • 化疗方案为卡铂/顺铂联合依托泊苷,放疗为每日两次、45 Gy/30次。
  • 收集放射性肺炎的发生与治疗结局数据,分析其与全肺剂量体积直方图参数的关系,并对≥2级放射性肺炎进行单因素和多因素分析。

主要发现

  • 患者中位年龄65岁,男性占73.6%,II期占20%,III期占80.0%,中位随访时间73.1个月。
  • 1级、2级、3级放射性肺炎分别见于69例、17例、12例患者,未观察到4至5级放射性肺炎。
  • ≥2级放射性肺炎患者接受糖皮质激素治疗,未出现复发。
  • 放疗开始至放射性肺炎发生的中位时间为147天;3例在59天内发生,6例在60至89天,16例在90至119天,29例在120至149天,24例在150至179天,20例在≥180天发生。
  • 剂量体积直方图参数中,接受>30 Gy的肺体积百分比(V30)与≥2级放射性肺炎发生率关系最强,预测放射性肺炎发生的最佳阈值为V30≥20%。

关键数值与推荐

  • 多因素分析显示V30≥20%为≥2级放射性肺炎的独立危险因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to clarify the characteristics of and evaluate the risk factors for radiation pneumonitis (RP) induced by chemoradiation therapy (CRT) using accelerated hyperfractionated (AHF) radiation therapy (RT) in patients with limited-stage small cell lung cancer (LS-SCLC). METHODS AND MATERIALS: Between September 2002 and February 2018, 125 patients with LS-SCLC were treated with early concurrent CRT using AHF-RT. Chemotherapy was comprised of carboplatin/cisplatin with etoposide. RT was administered twice daily (45 Gy/30 fractions). We collected data regarding onset and treatment outcomes for RP, and analyzed the relationship between RP and total lung dose-volume histogram findings. Uni- and multivariate analyses were performed to assess patient- and treatment-related factors for grade ≥2 RP. RESULTS: The median age of patients was 65 years, and 73.6% of participants were men. In addition, 20% and 80.0% of participants presented with disease stage II and III, respectively. The median follow-up time was 73.1 months. Grades 1, 2, and 3 RP were observed in 69, 17, and 12 patients, respectively. Grades 4 to 5 RP were not observed. RP was treated with corticosteroids in patients with grade ≥2 RP, without recurrence. The median time from initiation of RT to onset of RP was 147 days. Three patients developed RP within 59 days, 6 within 60 to 89 days, 16 within 90 to 119 days, 29 within 120 to 149 days, 24 within 150 to 179 days, and 20 within ≥180 days. Among the dose-volume histogram parameters, the percentage of lung volume receiving >30 Gy (V30) was most strongly related to the incidence of grade ≥2 RP, and the optimal threshold to predict RP incidence was V30 ≥20%. On multivariate analysis, V30 ≥20% was an independent risk factor for grade ≥2 RP. CONCLUSIONS: The incidence of grade ≥2 RP correlated strongly with a V30 of ≥20%. Contrarily, the onset of RP induced by concurrent CRT using AHF-RT may occur later. RP is manageable in patients with LS-SCLC.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Doshita K, Tabuchi Y, Kenmotsu H, et al. Incidence and Treatment Outcome of Radiation Pneumonitis in Patients With Limited-stage Small Cell Lung Cancer Treated With Concurrent Accelerated Hyperfractionated Radiation Therapy and Chemotherapy. Adv Radiat Oncol. 2022. PMID: 36845617. doi:10.1016/j.adro.2022.101129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。